Testosterone therapy for women has one well-supported use in research: low sexual desire causing distress after menopause. Evidence for energy, mood or muscle is thin. Here's what studies found, and how TelosRX providers think about hormone questions.
Testosterone isn't just a "male" hormone. Women make it in the ovaries and adrenal glands, and levels fall gradually with age. So it's no surprise that "testosterone therapy for women" keeps climbing in Google searches.
The research is more specific than the hype. This review walks through the key studies, finding by finding. It's evidence, not a promise. Any hormone plan is subject to medical approval by a licensed provider.
The Short Version: What the Evidence Supports
Before the details, here's how the main questions stack up across the research.
| Question | Strength of evidence | Key source |
|---|---|---|
| Low sexual desire with distress (postmenopausal) | Strong: multiple randomized trials | 2019 Lancet meta-analysis |
| Low desire before menopause | Limited | Small trials only |
| Mood, energy, wellbeing | Insufficient | 2019 Global Consensus |
| Muscle, bone, body composition | Insufficient (few women studied) | 2019 Lancet meta-analysis |
| Cognition | No effect shown so far | 2019 Lancet meta-analysis |
| Long-term safety | Not yet established | All major reviews |
Finding 1: A Large Meta-Analysis Confirmed Benefits for Sexual Function
The biggest summary to date pooled 36 randomized trials with 8,480 participants. It was published in The Lancet Diabetes & Endocrinology in 2019. Trials had to be blinded and last at least 12 weeks.
In postmenopausal women, testosterone improved satisfying sexual events, desire, pleasure, arousal, orgasm and self-image. It also reduced sexual distress. The authors concluded testosterone is effective for postmenopausal women with low desire that causes distress.
The effect sizes were moderate, not dramatic. In most trials, that meant under one extra satisfying sexual event per month on average. Some women respond more than that. Others notice little.
Finding 2: The Route of Delivery Changes the Lipid Picture
The same meta-analysis split results by how testosterone was given. Oral testosterone raised LDL cholesterol and lowered HDL cholesterol. Non-oral forms, like patches and creams, showed no such lipid shift.
That's why researchers prefer transdermal delivery, meaning applied to the skin. It's a practical finding that shapes how providers think about form, not just dose.
Finding 3: A Global Consensus Drew Clear Lines
Also in 2019, a panel from major menopause and endocrine societies issued a Global Consensus Position Statement on testosterone for women. It named one evidence-based indication: hypoactive sexual desire disorder (HSDD) in postmenopausal women.
The panel found insufficient data for any other symptom or condition. It advised keeping blood levels within the normal premenopausal female range. It also advised against products made for men, since those doses are far too high for women.
Finding 4: Common Side Effects Are Androgenic and Dose-Related
Across trials, testosterone raised the odds of acne and unwanted hair growth. These are called androgenic effects. Weight rose slightly on average. No serious adverse events were recorded in the pooled trial data.
- More common: acne, increased facial or body hair
- Less common at physiologic doses: scalp hair thinning, voice deepening, clitoral enlargement
- Why dose matters: higher blood levels raise the risk of lasting changes
Voice changes may not reverse after stopping. That's one reason providers monitor levels closely and start low.
Finding 5: Breast and Heart Safety Data Look Reassuring but Short
Breast cancer and heart risk are the questions women ask most. Short-term trial data haven't shown a clear increase in either. A 2024 claims-database study in The Journal of Sexual Medicine also found no link to higher cardiovascular or breast cancer risk.
The honest caveat: long-term safety data don't exist yet. Most trials ran months, not decades. The consensus panel and the Lancet authors both called for longer studies. Women with a history of hormone-sensitive cancer need specialist input.
Finding 6: No Testosterone Product Is FDA-Approved for Women
In the US, no testosterone product is FDA-approved for use in women. Prescribing for women is off-label, often using a fraction of a male-dosed gel. Compounded testosterone creams are also used, and they are not FDA-approved.
This doesn't mean testosterone use in women is illegal. It means a licensed provider has to weigh evidence, dosing and monitoring carefully. TelosRX operates as an asynchronous telehealth service, so any hormone question starts with a provider review of your intake. See current TelosRX pathways to learn what's offered.
Finding 7: Evidence Before Menopause Is Much Thinner
Most trials enrolled postmenopausal women, often after surgical menopause. Data for premenopausal women come from a handful of small studies. Results there were mixed and short-term.
The 2019 consensus panel did not recommend testosterone for premenopausal women outside research settings. Pregnancy risk is another concern, since testosterone can affect a developing fetus. Effective contraception is a standard requirement in any study that includes younger women.
How Researchers Measured "Better"
It helps to know what the trials actually counted. Most used validated questionnaires and sexual diaries rather than hormone levels alone.
- Satisfying sexual events: logged in a diary, usually over four-week windows
- Desire and arousal scores: rated on standardized questionnaires
- Distress scores: how much low desire bothered the participant
- Safety labs: lipids, liver function and blood counts
This matters because a blood level alone doesn't define success. Symptom change, measured carefully, is what the evidence is built on.
What This Means If You're Considering It
The research supports a narrow, well-defined use. It doesn't support testosterone as a general energy or anti-aging fix for women. If low desire is your concern, a provider will also look at other causes first.
- Relationship, stress and sleep factors
- Medications that dampen desire, like some antidepressants
- Estrogen status and menopause symptoms
- Thyroid function and iron levels
Other options exist too. Our guide to PT-141 for women and HSDD covers a different approach, approved by the FDA as the brand Vyleesi for premenopausal HSDD. You can also read what research shows on DHEA for women, or review our TRT telehealth evaluation guide.
Frequently Asked Questions
What does testosterone therapy do for women?
In research, testosterone therapy's clearest benefit for women is improved sexual desire, arousal and satisfaction in postmenopausal women with low desire causing distress. That conclusion comes from a 2019 meta-analysis of 36 trials. Evidence for mood, energy, muscle, bone and cognition is limited or absent. Results vary, and therapy requires a licensed provider's evaluation and monitoring.
What are the risks of testosterone therapy for women?
The most common risks are acne and unwanted hair growth, which rise with higher doses. Less often, women report scalp hair thinning or voice deepening, which may not reverse. Oral forms can worsen cholesterol levels. Long-term safety, including breast and heart effects, has not been fully established. A provider monitors blood levels to keep them in range.
Is testosterone therapy for women FDA-approved?
No. No testosterone product is currently FDA-approved for women in the US. Providers who prescribe it do so off-label, usually with small doses of a transdermal product. Compounded testosterone creams are also not FDA-approved. That makes careful dosing, lab monitoring and provider oversight especially important for any woman considering it.
Can testosterone therapy help women with low energy or mood?
Some women report better energy or mood, but the evidence doesn't confirm it. The 2019 Global Consensus found insufficient data to support testosterone for any symptom beyond low sexual desire in postmenopausal women. Fatigue and low mood have many causes, including thyroid issues, iron deficiency, poor sleep and depression. A provider can help sort those out first.
How is testosterone given to women?
Research favors transdermal delivery, meaning a cream or gel applied to the skin. The Lancet meta-analysis found non-oral forms avoided the negative cholesterol changes seen with oral testosterone. Doses are much lower than for men. Blood levels are typically checked a few weeks after starting to confirm they stay within the normal female range.
TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service.
Start your private evaluation at TelosRX.